BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30848214)

  • 1. Establishment and Characterization of Pemetrexed-resistant NCI-H460/PMT Cells.
    Xu YL; Jiang XM; Zhang LL; Chen X; Huang ZJ; Lu JJ
    Anticancer Agents Med Chem; 2019; 19(6):731-739. PubMed ID: 30848214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance.
    Yabuki N; Sakata K; Yamasaki T; Terashima H; Mio T; Miyazaki Y; Fujii T; Kitada K
    Cancer Genet Cytogenet; 2007 Feb; 173(1):1-9. PubMed ID: 17284363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
    Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
    Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
    Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
    Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs.
    Pesic M; Markovic JZ; Jankovic D; Kanazir S; Markovic ID; Rakic L; Ruzdijic S
    J Chemother; 2006 Feb; 18(1):66-73. PubMed ID: 16572896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
    Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
    BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
    Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
    Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro.
    Huang AC; Yang MD; Hsiao YT; Lin TS; Ma YS; Peng SF; Hsia TC; Cheng YD; Kuo CL; Chung JG
    J Ethnopharmacol; 2016 Dec; 194():1043-1050. PubMed ID: 27833027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line.
    Lei ZN; Teng QX; Zhang W; Fan YF; Wang JQ; Cai CY; Lu KW; Yang DH; Wurpel JND; Chen ZS
    Front Cell Dev Biol; 2020; 8():607275. PubMed ID: 33425914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
    Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
    BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between survivin expression and chemosensitivity of human lung cancer cells].
    Yang H; Fu JH; Hu Y; Huang WZ; Zheng B; Wang G
    Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(27):1934-7. PubMed ID: 17923022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
    Duan Z; Choy E; Jimeno JM; Cuevas Cdel M; Mankin HJ; Hornicek FJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1121-9. PubMed ID: 18828019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells.
    Liu DL; Li YJ; Yao N; Xu J; Chen ZS; Yiu A; Zhang CX; Ye WC; Zhang DM
    Eur J Pharmacol; 2014 Jun; 733():34-44. PubMed ID: 24704556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
    Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
    J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype.
    Yoon SS; Ahn KS; Kim SH; Shim YM; Kim J
    Lung Cancer; 2001; 33(2-3):221-8. PubMed ID: 11551417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.